Migrant and minority communities face higher rates of alopecia due to genetic, environmental, and cultural factors, needing better healthcare access and culturally aware treatments.
July 2025 in “Clinical Cosmetic and Investigational Dermatology” Major depression disorder increases the risk of alopecia areata, and vice versa.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
2 citations
,
May 2025 in “The Journal of Dermatology” Alopecia areata causes significant stigma and emotional distress, with many affected individuals not receiving adequate support or treatment.
1 citations
,
January 2025 in “JEADV Clinical Practice” Disease-specific tools better assess alopecia areata's impact on quality of life.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
May 2026 in “Indian Journal of Dermatology” Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
May 2026 in “Endocrine Connections” Androgenetic alopecia in PCOS is linked to insulin resistance, inflammation, and genetics, not just hormones.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
November 2025 in “Frontiers in Pharmacology” Xiaozhi Yufa decoction may help treat hair loss by improving hair growth and reducing inflammation.